--- title: "InSilico Medicine Cayman TopCo (3696) news: convertible notes" url: "https://aibio.space/companies/insilico-medicine-cayman-topco/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "3696 convertible notes news: InSilico Medicine plans US$305 million convertible bond sale. InSilico Medicine Cayman TopCo (HKEX: 3696), Hong Kong." --- 3696 InSilico Medicine Cayman TopCo HKEX · Hong Kong # InSilico Medicine Cayman TopCo (3696) news 3696 convertible notes news Debt Financing · 2026-08-28 ## [InSilico Medicine plans US$305 million convertible bond sale](https://aibio.space/news/insilico-medicine-plans-us-305-million-convertible-bond-sale/) The company agreed on August 27, 2026 to issue convertible bonds with an initial conversion price of HK$58.07 per share. ## Latest InSilico Medicine Cayman TopCo news We have not published a story on InSilico Medicine Cayman TopCo yet. When there is news, it will appear here. ## InSilico Medicine Cayman TopCo at a glance - **Ticker**: 3696 - **Listing**: HKEX - **Country**: Hong Kong ### Related companies - [Grand Pharmaceutical Group](https://aibio.space/companies/grand-pharmaceutical/) HKEX: 512 - [Dawnrays Pharmaceutical Holdings](https://aibio.space/companies/dawnrays-pharmaceutical/) HKEX: 2348 - [Tianda Pharmaceuticals](https://aibio.space/companies/tianda-pharmaceuticals/) HKEX: 455 - [SSY Group](https://aibio.space/companies/ssy/) HKEX: 2005 - [China Resources Pharmaceutical Group](https://aibio.space/companies/china-resources-pharmaceutical/) HKEX: 3320 - [Sanai Health Industry Group Company](https://aibio.space/companies/sanai-health-industry/) HKEX: 1889 - [Shenzhen Neptunus Interlong Bio-Technique Co.](https://aibio.space/companies/shenzhen-neptunus-interlong-bio-technique/) HKEX: 8329 - [HUTCHMED (China)](https://aibio.space/companies/hutchmed-china/) HKEX: 13 ### Also on HKEX - [Everest Medicines](https://aibio.space/companies/everest-medicines/) 1952 - [Duality Biotherapeutics](https://aibio.space/companies/duality-biotherapeutics/) 9606 - [Jacobson Pharma Corporation](https://aibio.space/companies/jacobson-pharma/) 2633 - [Transcenta Holding](https://aibio.space/companies/transcenta/) 6628 - [Ascletis Pharma](https://aibio.space/companies/ascletis-pharma/) 1672 - [Wuhan YZY Biopharma Co.](https://aibio.space/companies/wuhan-yzy-biopharma/) 2496 ## Questions about InSilico Medicine Cayman TopCo Has InSilico Medicine Cayman TopCo sold convertible notes? Our latest story on this, dated Aug 28, 2026: "InSilico Medicine plans US$305 million convertible bond sale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/insilico-medicine-plans-us-305-million-convertible-bond-sale/). What is the ticker symbol of InSilico Medicine Cayman TopCo? InSilico Medicine Cayman TopCo trades under the ticker 3696 on HKEX. Where is InSilico Medicine Cayman TopCo listed? InSilico Medicine Cayman TopCo is listed on HKEX. Our directory also records these other listings: GETTEX:O15; LS:A41XT7; LSX:A41XT7; OTC:IMDCY; OTC:ISLMF. Which country or territory is InSilico Medicine Cayman TopCo listed under? Our directory records InSilico Medicine Cayman TopCo under Hong Kong. What does InSilico Medicine Cayman TopCo do? Our directory classifies InSilico Medicine Cayman TopCo as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of InSilico Medicine Cayman TopCo? The ISIN recorded for InSilico Medicine Cayman TopCo is KYG4790P1037. Does aibio.space cover InSilico Medicine Cayman TopCo? aibio.space lists InSilico Medicine Cayman TopCo among 2,820 public biotech companies and publishes its news here as stories appear. What is the latest InSilico Medicine Cayman TopCo (3696) stock news? Our latest story on InSilico Medicine Cayman TopCo, dated Aug 28, 2026: "InSilico Medicine plans US$305 million convertible bond sale". The company agreed on August 27, 2026 to issue convertible bonds with an initial conversion price of HK$58.07 per share. [Source](https://aibio.space/news/insilico-medicine-plans-us-305-million-convertible-bond-sale/). Which companies are similar to InSilico Medicine Cayman TopCo? Companies in our directory listed in the same country and business area as InSilico Medicine Cayman TopCo: Grand Pharmaceutical Group, Dawnrays Pharmaceutical Holdings, Tianda Pharmaceuticals, SSY Group, China Resources Pharmaceutical Group, Sanai Health Industry Group Company. How can I follow InSilico Medicine Cayman TopCo (3696) news? Press Follow on this page to add InSilico Medicine Cayman TopCo to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming InSilico Medicine Cayman TopCo so far, in Debt Financing. ## Investor discussion: InSilico Medicine Cayman TopCo Members talk about InSilico Medicine Cayman TopCo (3696). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at InSilico Medicine Cayman TopCo, newest first. Each line links the filing it comes from. 1. 2026-09-03 Financings Share or debt issue: COMPLETION OF THE ISSUE OF US$305,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2027 UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0903/2026090302431.pdf) 2. 2026-08-27 Financings Share or debt issue: PRICING OF US$305,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2027. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082800033.pdf) 3. 2026-04-30 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0430/2026043000333.pdf) 4. 2026-04-28 Financings Share or debt issue: PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS AND PROPOSED RE-APPOINTMENT OF AUDITOR AND NOTICE OF THE ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042803665.pdf) 5. 2025-12-17 Financings Share or debt issue: GLOBAL OFFERING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1218/2025121800031.pdf) ## Press releases Headlines of InSilico Medicine Cayman TopCo's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-27 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE REPORTS PRELIMINARY POSITIVE FIRST-IN-HUMAN CLINICAL TRIAL DATA FOR ISM6331 DESIGNED USING GENERATIVE AI IN MESOTHELIOMA AND OTHER SOLID TUMORS AT ESMO 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1027/2026102700060.pdf) 2. 2026-10-20 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE TRIGGERS A MILESTONE PAYMENT IN AI-DRIVEN R&D COLLABORATION WITH SERVIER FOR ACHIEVING EARLY DRUG DISCOVERY MILESTONE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1020/2026102000129.pdf) 3. 2026-10-13 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES PERIPHERAL-RESTRICTED VAV1 MOLECULAR GLUE DEGRADER FOR POTENTIAL TREATMENT OF AUTOIMMUNE DISEASES](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1013/2026101300035.pdf) 4. 2026-09-30 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES NEXT-GENERATION SMALL MOLECULE GIPR ANTAGONIST FOR POTENTIAL INTERVENTION OF OBESITY AND RELATED DISORDERS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0930/2026093000283.pdf) 5. 2026-09-21 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE ENTERED INTO AN AI CO-DEVELOPMENT COLLABORATION WITH A CONTRACT VALUE UP TO TENS OF MILLIONS OF U.S. DOLLARS TO BUILD AND COMMERCIALIZE FOUNDATION MODELS FOR BIOLOGY](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0921/2026092100349.pdf) 6. 2026-09-14 HKEXnews [VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0914/2026091400111.pdf) 7. 2026-09-10 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE COMPLETED FIRST PATIENT ENROLLMENT AND DOSING IN PHASE III (GENESIS-IPF-3) CLINICAL TRIAL OF RENTOSERTIB, ITS LEADING AI-DRIVEN INNOVATIVE DRUG CANDIDATE FOR IPF](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0910/2026091000093.pdf) 8. 2026-09-04 HKEXnews [VOLUNTARY ANNOUNCEMENT SHARE INCREASING PLAN BY THE CHAIRMAN OF THE BOARD](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0904/2026090400061.pdf) 9. 2026-09-03 HKEXnews [COMPLETION OF THE ISSUE OF US$305,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2027 UNDER GENERAL MANDATE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0903/2026090302431.pdf) 10. 2026-08-27 HKEXnews [PRICING OF US$305,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2027](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082800033.pdf) 11. 2026-08-26 HKEXnews [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082600474.pdf) 12. 2026-08-18 HKEXnews [VOLUNTARY ANNOUNCEMENT POSSIBLE PARTICIPATION IN THE ESTABLISHMENT OF AN INVESTMENT FUND](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0818/2026081801100.pdf) 13. 2026-08-17 HKEXnews [VOLUNTARY ANNOUNCEMENT INCLUSION IN MSCI GLOBAL SMALL CAP INDEXES](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081700141.pdf) 14. 2026-08-03 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE RECEIVES NMPA IND APPROVAL FOR ISM8969/HT-001, THE BLOOD-BRAIN-BARRIER-PENETRANT NLRP3 INHIBITOR CO-DEVELOPED WITH HYGTIA THERAPEUTICS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0803/2026080300063.pdf) 15. 2026-07-29 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE RECEIVES FDA FAST TRACK DESIGNATION FOR ISM6331 IN ADVANCED MESOTHELIOMA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0729/2026072900099.pdf) 16. 2026-07-27 HKEXnews [VOLUNTARY ANNOUNCEMENT ISM6331 PHASE I CLINICAL DATA IN PATIENTS WITH MESOTHELIOMA AND ADVANCED SOLID TUMORS ACCEPTED FOR RAPID ORAL PRESENTATION AT ESMO CONGRESS 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0727/2026072700047.pdf) 17. 2026-07-15 HKEXnews [RESIGNATION OF NON-EXECUTIVE DIRECTORS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0715/2026071501405.pdf) 18. 2026-07-15 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND BORA PHARMACEUTICALS ANNOUNCED A STRATEGIC ALLIANCE FOR AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0715/2026071500065.pdf) 19. 2026-07-13 HKEXnews [VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND CMS ENTER INTO AN ADDITIONAL DRUG DEVELOPMENT COLLABORATION IN THE FIELDS OF CENTRAL NERVOUS SYSTEM DISEASES](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0713/2026071300017.pdf) 20. 2026-07-09 HKEXnews [POSITIVE PROFIT WARNING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0709/2026070900039.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:3696 on TradingView](https://www.tradingview.com/symbols/HKEX-3696/). ## Listing details InSilico Medicine Cayman TopCo is a public biotech or pharmaceutical company listed on HKEX under the ticker 3696, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: InSilico Medicine Cayman TopCo - **Ticker**: 3696 - **Listing**: HKEX - **Country or territory**: Hong Kong - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG4790P1037 - **Other listed symbols**: GETTEX:O15; LS:A41XT7; LSX:A41XT7; OTC:IMDCY; OTC:ISLMF - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-3696/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/insilico-medicine-cayman-topco/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "InSilico Medicine Cayman TopCo (3696) news: convertible notes", 2026-10-31, https://aibio.space/companies/insilico-medicine-cayman-topco/